Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of DWN12088 in Idiopathic Pulmonary Fibrosis
NCT05389215Phase 2Active, not recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing DWN12088 Xmg Tablet (BID) with Placebo 0mg Tablet (BID) (2 arms). Primary endpoints: Rate of decline of Forced Vital Capacity at 24 weeks and Incidents of treatment-emergent adverse events at 24 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
DWC202201
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05389215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389215.